Companies › Leal Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Psychiatry, Neurology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LTX-001 | – | Phase 1 | Schizophrenia | Mar 2027 |
| LTX-002 Antisense oligonucleotide (ASO) targeting SPTLC1 mRNA | SPTLC1 | Phase 1 | Amyotrophic Lateral Sclerosis | Jun 2031 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07734493 | LTX-001 | Phase 1 | Schizophrenia | Psychiatry | Mar 2027 |
| NCT07660614 | LTX-002 | Phase 1 | Amyotrophic Lateral Sclerosis | Neurology | Jun 2031 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.